News Hub | News Direct

Goodway Cares Donates Over $27K to Local Washington D.C. Charities During Bi-Annual Off-Site

Goodway Group

Goodway Cares, a 501(c)(3) charity arm of Goodway Group, is proud to announce donations totaling $27,285 to three local charities following Goodway Group’s annual all-company summit. During the summit, Goodway Cares hosted the Circle of Gratitude on the engagement floor, where Goodway employees shared gratitude and came together to support Washington D.C.-based organizations. Through employee votes, the Circle of Gratitude selected Hero Dogs ($10,095), An Open Book Foundation ($9,095), and Together We Bake ($8,095) as recipients of this year’s donations. The incremental $95 is a tribute to Goodway Group’s 95-year history. Hero Dogs: Based in Maryland, Hero Dogs is a 501(c)(3) non-profit organization dedicated to improving the quality of life for our nation’s heroes by placing assistance dogs with veterans of the U.S. military and first-responders with disabilities. Hero Dogs provides customized training and lifetime support to enhance the services of community organizations. An Open Book Foundation: Founded in 2010 by Dara La Porte and Heidi Powell, An Open Book Foundation aims to connect authors with students in under-resourced schools. By bringing authors into schools and providing free books, the foundation fosters a love of reading and learning. Since its inception, An Open Book has hosted numerous events and donated thousands of books to students and libraries. Together We Bake: Together We Bake’s mission is to empower women facing barriers to employment by providing a comprehensive workforce training and personal development program. This initiative helps participants gain self-confidence, transferable workforce skills, and hands-on experience, paving the way for sustainable employment and self-sufficiency. Nikki Charles, executive director of Hero Dogs, stated, “We’re thrilled to partner with Goodway Cares. With their support, we’re able to give more veterans and first-responders the service dogs they need.” For more information about Goodway Cares, please visit goodwaygroup.com/goodway-cares. About Goodway Cares: Goodway Cares, a 501©(3) charity arm of Goodway Group, provides business support to budding non-profit organizations who are helping shape a brighter tomorrow. Goodway Cares provides support to non-profits in varying methodologies including strategy, consultation, media activation, and financial donations. Goodway Cares is funded through Goodway Group employee contributions and employee’s volunteering their time for non-profit support. About Goodway Group: Goodway Group is a leading independent digital marketing agency fueled by data, technology and a dedicated purpose of making your media investment perform. Goodway Group’s Outcome Engineering™ powers our full ecosystem, a proprietary philosophy that connects strategy, analytics and precise execution for measurable growth. Goodway Group ranks among the top North American agencies, earning prestigious awards for innovative marketing technology, impactful work and fostering inclusive, remote-first workplaces. We've been honored as a multiyear Ad Age Best Places to Work and received AdExchanger’s Best Use of Technology by an Agency award among other accolades. Our collective media buying power has led to industry-renowned partnerships. We hold certifications and are recognized with preferred partner status across the Triopoly and all major marketing and media platforms. This ensures that our clients' media investments are optimally managed, minimizing fraud and waste, and maximizing effectiveness and value. Our company encompasses five distinct divisions: CvE, a marketing advisory firm; G-Comm, a retail media accelerator; TUFF, a performance marketing agency; Goodway, a managed service media and analytics partner; and GRADIANT, a modern funnel digital media agency. Together, we make up Goodway Group, the marketing engine that unlocks measurable growth for the world's most progressive brands. Contact Details Kite Hill PR for Goodway Group +1 973-722-7881 goodway@kitehillpr.com Company Website https://www.goodwaygroup.com/

August 12, 2024 10:00 AM Eastern Daylight Time

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder

MarketJar

Major Depressive Disorder (MDD) was the third leading cause of global disease burden in 2008, according to the World Health Organization, with projections that it could become the leading cause by 2030. MDD is a severe mental health condition marked by persistent sadness, loss of interest in activities, and difficulties in daily functioning. 1 Lithium, a well-known mood stabilizer, has been used off-label for MDD, but its application is limited by safety concerns due to its narrow therapeutic window. In response to this unmet need, Alzamend Neuro, Inc. (NASDAQ:ALZN), a clinical-stage biopharmaceutical company, is dedicated to developing innovative treatments for neurological and psychiatric disorders, including MDD. The company's latest effort involves a promising partnership with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001, a next-generation lithium-based therapeutic candidate aimed at improving the safety and effectiveness of lithium treatment for MDD. Dr. Ovidiu Andronesi, an Associate Professor of Radiology at Harvard University, will lead the study. This trial aims to compare AL001's effectiveness and safety against a marketed lithium carbonate product by examining lithium levels in the brain and its structures. Alzamend Neuro, Inc. (NASDAQ:ALZN) previously completed a Phase IIA trial that identified a maximum tolerated dose (MTD) for AL001. This dose is designed to provide lithium at a safe and effective level without the need for frequent monitoring, unlike current lithium treatments that are limited by chronic toxicity and poor physicochemical properties. The primary goal of this study is to determine the ideal dose of AL001 that can achieve similar or better effectiveness and safety compared to existing lithium salts. Alzamend is optimistic that the study will meet regulatory safety standards through the FDA's Section 505(b)(2) pathway, which allows for new formulations of approved drugs. Stephan Jackman, Chief Executive Officer of Alzamend Neuro, Inc. (NASDAQ:ALZN), expressed enthusiasm about the partnership with Massachusetts General Hospital and Dr. Andronesi for the pivotal study of AL001. He highlighted the potential of AL001 to be a next-generation lithium product with an improved safety profile and enhanced brain biodistribution, which could eliminate the need for routine therapeutic drug monitoring (TDM). Jackman emphasized that developing such a product would represent a significant advancement over existing lithium-based treatments and could have a positive impact on the over 21 million Americans affected by Major Depressive Disorder (MDD). Alzamend plans to share more details about the study’s timeline and market opportunities in the near future. Alzamend Neuro and Massachusetts General Hospital Launch Phase II Trials of AL001 for Bipolar Disorder and Alzheimer’s Alzamend Neuro, Inc. (NASDAQ:ALZN) is also partnering with MGH to conduct Phase II clinical trials of AL001 for patients with bipolar disorder (BD) and Alzheimer’s disease. These trials are also led by Dr. Ovidiu Andronesi, an Associate Professor of Radiology at Harvard University. Lithium, the first mood stabilizer approved by the U.S. Food and Drug Administration (FDA), remains the gold standard for treating bipolar disorder (BD). With over 35 years of use, its safety profile is well established, which may reduce regulatory hurdles. This trial aims to compare the increase in brain lithium levels between AL001 and a commonly marketed lithium salt in BD patients, seeking to optimize dosing for enhanced effectiveness and safety. As for the Alzheimer’s trial, a cohort of healthy subjects will be studied to compare their plasma and brain pharmacokinetics with those of Alzheimer's patients. This trial aims to evaluate the increase in brain lithium levels and its distribution between AL001 and a commonly marketed lithium salt in both Alzheimer's patients and healthy subjects. Alzamend Neuro Secures $25 Million Funding to Advance Clinical Trials Alzamend Neuro, Inc. (NASDAQ:ALZN) recently secured the initial two tranches under a $25 million purchase agreement. This investment will drive the progress of Alzamend 's clinical trials and the development of next-generation treatments for Alzheimer’s, bipolar disorder, MDD, and PTSD. CEO Stephan Jackman highlighted the company’s commitment to achieving clinical milestones and transforming lithium-based therapies for millions of people affected by these conditions. Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN). [1] https://www.ncbi.nlm.nih.gov/books/NBK559078/ Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

August 12, 2024 09:30 AM Eastern Daylight Time

Image

Open Letter Demands ‘Newsroom Reset’, Pushes for Adoption of Pro-Democracy Election Coverage Guidelines

Media and Democracy Project

Today, the Media and Democracy Project (MAD), along with 3,258 individuals, sent an open letter to executives, publishers, and union leaders of major media organizations urging them to adopt pro-democracy election coverage guidelines ( PDF ) that center fact-based reporting, push back against election lies, and uplift voting. MAD’s proposed guidelines respectfully request newsrooms switch their focus from polls and drama to candidates’ policies, past-governance, and behavior. “It’s time that newsrooms start to cover elections like they matter more than sports scores,” said Brian Hansbury, cofounder of MAD. “Our democratic institutions are under attack and it’s incumbent on newsrooms to recalibrate their political coverage to adopt and adhere to practices that are pro-truth, pro-voting, and pro-democracy.” MAD’s guidelines contain 18 recommendations organized into three categories—a focus on substantive issues coverage, extensive reporting on threats to democracy, and protecting Americans against the spread of disinformation. The guidelines provide specific actions reporters and editors can take to ensure practices that help voters make informed decisions at the ballot box. They include: Prioritize substantive coverage of the issues that matter to voters' lives; Make headlines accurate and informative, not clickbait; Stop making predictions and pushing polls at the expense of issue coverage; Celebrate and uplift election workers, voters, and the election process; Don’t set aside moral judgment when covering obvious lies and bigotry; Hold politicians to account for their positions, statements, and behavior, as well as those of their party’s leader; Expose candidates who foment political violence. The open letter emphasizes how crucial it is for voters to understand what’s at stake in November and the damaging impact that election lies have already had on our democracy. For instance, lies about the 2020 election have caused a spike in death threats for election officials and poll workers, making it difficult to recruit and retain them. Half of all female state legislators are considering leaving public office due to increased intimidation. Meanwhile, Trump allies are preparing plans like Project 2025, which would harm millions of Americans and cripple our democratic system. With 3,258 signatures and counting, the letter includes signatories such as Ruth Ben-Ghiat, NYU Professor of History and author of Strongmen: Mussolini to the Present and the Lucid newsletter, who stated, "It's never been more important for news organizations to analyze the threats to U.S. democracy in clear and precise terms. Americans deserve to know the scale and nature of the challenges we face this November and beyond." The rights and freedoms that Americans cherish are at risk. As an essential pillar of democracy, journalists and the news media have a moral responsibility to inform Americans about anti-democratic extremist movements. Another signatory, Mark Jacob, former Chicago Tribune editor and author of the Stop the Presses newsletter, said, “The news media know it's their job to warn people when a hurricane is bearing down on them. But when a fascist assault on our democracy is bearing down on them, the media sometimes think it would be biased to warn people about it. That has to change before it's too late.” It’s more important than ever for journalists, editors, and their publishers to step up and put the public before profit, democracy before tyranny, and truth before lies. "Democracy is at stake–and as the open letter so powerfully demands, we need our news media to step up and be responsible,” said Norm Ornstein, political scientist and Senior Fellow Emeritus at the American Enterprise Institute. To learn more about this effort advocating for pro-democracy election coverage, and see who else signed the open letter visit MAD’s website. The Media and Democracy Project: MAD is a non-partisan, all-volunteer, grassroots organization focused on strengthening a free and independent media in the public interest. MAD aims to improve our national discourse so that American voters can engage in informed decision-making. As part of that goal, MAD has an interest in the responsibility of journalists and media to report fully, accurately, and fairly on the electoral process and the outcome of elections. Additional information is available at www.MediaAndDemocracyProject.Org. Contact Details Aaron Alberico +1 202-744-0786 aalberico@raynoravenue.com Company Website https://www.mediaanddemocracyproject.org/

August 12, 2024 09:00 AM Eastern Daylight Time

Benchmark International Unveils the 2024 Global Healthcare & Medical Industry Report

Benchmark International

Benchmark International, a leading global mergers and acquisitions firm, proudly announces the release of its 2024 Global Healthcare & Medical Industry Report. This in-depth report offers valuable insights into the current trends, challenges, and opportunities within the healthcare and medical sectors. The 2024 Global Healthcare & Medical Industry Report highlights the significant growth and transformation these industries are experiencing. With advancements in technology, increased investment, and evolving regulatory landscapes, the report provides a comprehensive analysis of the factors driving change and the potential impact on businesses operating within these sectors. Key Highlights of the Report Include: Market Growth and Trends: An overview of the rapid growth in the healthcare and medical industries, including key market trends, emerging technologies, and areas of significant investment. Mergers and Acquisitions Activity: An analysis of recent M&A transactions, highlighting notable deals, and providing insights into the strategic motivations behind these acquisitions. Regulatory and Compliance Challenges: A detailed examination of the evolving regulatory environment and its implications for businesses, including key compliance issues and strategies to navigate them. Future Outlook: Predictions and projections for the future of the healthcare and medical industries, identifying potential growth areas and challenges businesses may face in the coming years. Benchmark International is committed to delivering unparalleled expertise and insights to its clients. The release of this report underscores the firm's dedication to staying at the forefront of industry trends and providing actionable intelligence to support business growth and success. For more information and to access the full 2024 Global Healthcare & Medical Industry Report, please visit: https://www.benchmarkintl.com/insights/featured-content/2024-global-healthcare-medical-industry-report/ ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 zoeller@benchmarkintl.com Company Website https://www.benchmarkintl.com/

August 12, 2024 09:00 AM Eastern Daylight Time

Image

News Release

Elf Labs’ CEO Opening Live Q&A for Investors Amid Private Capital Raise

Elf Labs

Elf Labs, which owns the intellectual property behind iconic characters like Cinderella, Snow White, and Peter Pan, is hosting an exclusive investor presentation and Q&A session as part of their latest capital raise. Led by CEO David Phillips, the presentation will take place on August 15th at 2 PM ET. Investors attending the webinar will be eligible for an additional 5% bonus shares if they attend at least 10% of the total webinar time. Elf Labs’ Promising Property Portfolio With over 100 trademarks and 400 international copyrights secured, Elf Labs is poised to monetize these assets in the 2T entertainment and merchandise market. Their licenses include Rapunzel, Sleeping Beauty, and more. The company uses cutting-edge AR/VR technology to create high-resolution, immersive experiences. Their team includes Emmy award-winning creatives and former Disney Imagineers who have worked on franchises like Star Wars and Shrek. Multiple Markets in One Investment David Phillips, CEO of Elf Labs, says, “We are tapping into several revenue streams, including subscriptions, ad revenue, licensing royalties, and in-game purchases. This diversified approach ensures a steady income flow and reduces reliance on any single revenue source.” Elf Labs recently secured investment from MaryRuth's Organics and formed a strategic partnership with E.L.G Foods to create Princess-themed salty snacks with collectible add-ons. Phillips adds, “Elf Labs is not only creating new intellectual properties but also democratizing ownership. Investors will have a say in introducing new characters and will own a piece of the classic characters, fostering a deeper connection and sense of involvement.” Join Elf Labs’ Live Q&A Spaces for the event are limited. Interested investors are encouraged to register as soon as possible. Sign up for the live investor event by clicking the link below. Date & Time: Thursday, August 15th at 2 PM EST Speakers: David Phillips, CEO Billy Phillips, Chairman, Founder, and Head of Creative Reserve Your Spot Individuals who attend the webinar will be eligible to receive an additional 5% bonus shares on their investment in Elf Labs. To qualify, attendees simply need to participate in at least 10% of the total webinar time. This unique incentive underscores Elf Labs' commitment to engaging and rewarding its investor community. Elf Labs is a leading animation and technology company dedicated to creating immersive online environments. Combining award-winning creative talent and advanced AR/VR technology, Elf Labs produces high-quality animations that captivate audiences and set new standards in the industry. With a commitment to innovation and excellence, Elf Labs is poised to become a major player in the entertainment sector. Contact Details Elf Labs Investor Relations invest@elflabs.com Company Website https://www.elflabs.com/

August 12, 2024 09:00 AM Eastern Daylight Time

Revenue Management Solutions Named “Best Use of Research and Surveys” In PR Daily’s 2024 Social Media, Digital & Content Marketing Awards

Revenue Management Solutions

Revenue Management Solutions (RMS), a global leader in data-driven analytics and tech-enabled solutions for the restaurant industry, proudly announces its win at the 2024 Social Media, Digital & Content Marketing Awards, presented by PR Daily. For its impactful Restaurant Trend Reports, RMS took home the award in the "Use of Research/Surveys" category. The awards ceremony, held on August 1 at the prestigious Yale Club in New York City, celebrated the hidden stars and talents behind impressive social and content marketing campaigns. Attendees gathered to honor professionals across various categories, from Best Social Media Campaign to Digital Community Engagement. "Winning this award is a testament to our team's dedication and expertise in delivering insightful content that drives restaurant industry success," said Jana Zschieschang, RMS Chief Brand Officer. “Thousands of restaurant industry influencers access our Quick-Service Trend Report every month to gain clear and concise insights to navigate the ever-changing landscape of the restaurant business." RMS launched its QSR Trend Reports during the pandemic, a time of rapid change for the restaurant industry. What began as a tool to condense and simplify fast-food trends has evolved into a respected source for restaurant pricing, sales and traffic referenced by clients and leading news outlets, including Reuters, The Wall Street Journal, Bloomberg and trusted restaurant trade publications. PR Daily's Content Marketing Awards spotlight the most impactful and innovative work in the field. Brendan Gannon, Senior Marketing Manager for the Ragan/PR Daily Awards programs, praised RMS for their creative approach, noting “The winners set a new standard in content creation with exceptional storytelling and strategic insights. Their work exemplifies the power of data-driven content in capturing audience attention and driving meaningful results." As RMS celebrates this significant achievement, it continues to lead the industry in data-driven tech solutions that empower restaurant brands to confidently navigate challenges such as inflation and labor costs. For 30 years, Revenue Management Solutions has partnered with restaurant brands to deliver actionable insights and data-driven recommendations that boost sales, streamline costs, and maximize profitability. Their AI-powered solutions support over 100,000 locations worldwide, enabling brands to unlock the power of their data and thrive in a competitive market. About Revenue Management Solutions Revenue Management Solutions (RMS) partners with restaurant brands to provide data-driven solutions that drive sales, streamline costs, and enhance profitability. With AI-powered analytics, RMS supports over 100,000 locations globally, empowering brands to navigate industry challenges confidently. For more information, visit www.revenuemanage.com. About Ragan Communications and PR Daily Ragan Communications has been a trusted source of news, training, and intelligence for more than 50 years, serving internal and external communicators and business executives. PRDaily.com and Ragan.com are read by over 600,000 communicators monthly, providing insights and resources across various communication fields. Contact Details Tracy Henderson +1 720-989-3530 tracy@centerreachcommunication.com Company Website https://www.revenuemanage.com

August 12, 2024 08:33 AM Eastern Daylight Time

Innovayte and Advyzon Partner to Create Single, State-of-the-Art Technology Solution

Innovayte

Innovayte, a custody and clearing firm that supports entrepreneurial registered investment advisors (RIAs) and wealth managers, and Advyzon, a comprehensive technology platform and portfolio management solution for financial advisors and investment managers, today announced the launch of their groundbreaking, state-of-the-art platform and model marketplace. For Innovayte, Advyzon has created its first and only custodial back-end platform. The technology offers advisors a unique solution combining a separately managed account (SMA) and model marketplace with access to third-party asset managers – offered by Advyzon Investment Management (AIM), the turnkey asset management program under the Advyzon umbrella – all built from a unified managed account (UMA) framework. “Technology is critical to helping RIAs reach their entrepreneurial goals,” said Cat Davies, Chief Executive Officer of Innovayte. “To truly empower advisors, we needed a new and fresh technology solution, not the same archaic legacy systems that fail to address the industry’s diverse needs. We’re excited to partner with Advyzon to give our advisors all the tools they need to grow and scale.” A PARTNERSHIP TO PUSH THE ENTIRE INDUSTRY FORWARD Advyzon’s intuitive, cloud-based technology platform offers a single solution that combines portfolio management, customizable performance reporting, trading and rebalancing, client web portals, CRM, client billing, and SEC-compliant document storage, customized mobile app and portal, as well as the model marketplace and investment management from Innovayte’s UMA/SMA platform via Advyzon Investment Management. “We are proud to introduce the custody, clearing and investment management platform of the future,” said Lee Andreatta, CEO of Advyzon Investment Management. “When Innovayte approached us about a partnership, we jumped at the opportunity to help usher in a new era for financial custody and clearing, plus investment management. Unfortunately, most firms use outdated technology, and we hope this partnership helps push the entire industry forward.” The Innovayte platform is the only technology solution that can effectively serve the unique needs of high- and ultra-high-net-worth clients, given the UMA framework and its inclusion of a full rebalancer, model marketplace, and access to third-party managers. Key features include: Nucleus Model Marketplace, which gives advisors access to third-party strategists, risk models, and advisor-created models. Quantum Rebalancer, which gives advisors multiple rebalance and tactical trade tools, including location optimization, cash management, and tax-loss harvesting. Robust Trading Capabilities, including tax overlay and direct indexing options. SMA/UMA Structure, featuring single and multi-sleeve reporting and trading. To learn more about Innovayte, click here. To learn more about Advyzon, click here. About Innovayte Built from a heritage that spans a half century, Innovayte is a self-clearing custodian that fuels growth-minded advisors’ entrepreneurial spirit, helping wealth advisors to thrive. From cutting-edge technology through its proprietary Accelerayte platform, to pairing advisors with dedicated team members throughout our service model, Innovayte offers advanced technology and services with a human touch. For more information, visit Innovayte.com. About Advyzon Advyzon provides comprehensive, intuitive, cloud-based wealth management technology and investment management services for registered investment advisors (RIAs) and independent financial advisors. The Advyzon tech platform combines portfolio management, customizable performance reporting, trading and rebalancing, client web portals, client relationship management (CRM), client billing, and document storage, along with investment management services and a model marketplace offered by Advyzon Investment Management, LLC (AIM). A team of entrepreneurs led by CEO Hailin Li, Ph.D., CFA®, Advyzon strives to innovate in strategic and useful ways. Financial advisors inspire Advyzon’s innovation and integrations. Their exceptional technology and unmatched service exist to improve the advisor experience – whether it’s via portfolio and firm management or client relationships and growth. To learn more about Advyzon, visit Advyzon.com. Custody and administrative services provided by ETC Brokerage Services. Innovayte is an affiliate of ETC Brokerage Services. Neither Advyzon nor AIM are affiliates of Innovayte. AIM is a registered investment adviser registered with the United States Securities and Exchange Commission, and a wholly owned subsidiary of yHLsoft Inc., doing business as Advyzon ("Advyzon"). All investment advisory services are provided by AIM, while some technology and administrative support services are provided by Advyzon. AIM's advisory services are available to financial advisors for use in managing assets for their clients only, and do not provide advisory services directly to retail investors. Statements made by Innovayte in this communication that indicate approval, support, or recommendation of AIM are considered endorsements. These endorsements are made by representatives of Innovayte, and Innovayte has a business relationship with Advyzon and AIM. No cash compensation was paid to these parties for their statements; however, Advyzon and AIM receive compensation for their technology and investment management services provided through this platform. Contact Details For Innovayte Ray Hennessey, Vocatus rh@vocatusllc.com For Advyzon Jonny Swift, Impact Communications, Inc. +1 913-649-5009 JonnySwift@ImpactCommunications.org Company Website https://innovayte.com/

August 12, 2024 08:30 AM Eastern Daylight Time

News Release

Black Unicorn Factory Achieves $500 Million Milestone in Alternative Funding, Signaling a New Era in Venture Capital

Rev Up Marketers

Black Unicorn Factory announces the successful funding of over 150 businesses, totaling more than $500 million in alternative funding. This significant milestone reflects a shift in the venture capital landscape, emphasizing the viability and effectiveness of non-traditional investment models. The approach adopted by Black Unicorn Factory utilizes specific provisions within the Securities and Exchange Commission (SEC) regulations that permit investments in "cash or other consideration." By embracing this inclusive definition, Black Unicorn Factory has opened new avenues for businesses that may have been overlooked by conventional funding mechanisms. This strategy has provided essential capital to a diverse array of enterprises, facilitating growth, development, and preparation for public listing. Johnny Stewart, founder of Black Unicorn Factory, stated, "Many have overlooked the potential of 'other consideration' as stipulated in the SEC rules. Utilizing this provision has empowered businesses, particularly those owned by minorities, providing them with the capital necessary to thrive and eventually go public." The $500 million in alternative funding has not only fueled the expansion of numerous businesses but has also highlighted the potential of non-cash investments in driving economic growth. By focusing on alternative investment strategies, Black Unicorn Factory has demonstrated that wealth-building opportunities extend beyond traditional cash transactions. This perspective aligns with a broader movement within the venture capital industry toward diversification and inclusivity. The funded businesses span various industries, reflecting a commitment to supporting a wide range of entrepreneurial endeavors. By providing access to capital through alternative means, Black Unicorn Factory has enabled these enterprises to reach milestones that were previously considered unattainable. This achievement underscores the effectiveness of leveraging SEC rules to create innovative funding solutions. Black Unicorn Factory's model has also contributed to the broader economic empowerment of underrepresented communities. By focusing on minority-owned businesses, the company has played a role in fostering diversity within the entrepreneurial ecosystem. This approach resonates with current trends emphasizing social responsibility and equitable access to resources within the business community. The success of this funding model has positioned Black Unicorn Factory as a leader in the national venture capital arena. The innovative use of SEC provisions has set a precedent for others in the industry, illustrating the potential for alternative investments to reshape the funding landscape. This accomplishment serves as a testament to the possibilities that arise when traditional boundaries are challenged and redefined. As Black Unicorn Factory continues to expand its portfolio, the commitment to fostering a diverse and inclusive environment remains steadfast. The company's efforts not only support individual businesses but also contribute to the broader goal of creating a more equitable and dynamic economic landscape. By championing alternative investing, Black Unicorn Factory is paving the way for future innovations in venture capital. For additional information about Black Unicorn Factory and its work in alternative investing, please visit the company’s website at https://blackunicornfactory.com/ or contact via email at info@blackunicornfactory.com. Contact Details Black Unicorn Factory John Stewart info@blackunicornfactory.com Company Website https://blackunicornfactory.com/

August 12, 2024 06:40 AM Eastern Daylight Time

Therma Bright Inc. (OTCQB: TBRIF) (TSXV: THRM): Pioneering Growth in the Expanding Medical Devices Market

TBRIF

The medical device industry is expanding rapidly, propelled by technological advancements and rising healthcare demands around the world. The global medical devices market is on a growth trajectory, with a projected annual increase of 5.71%, reaching $673.10 billion by 2029, as reported by Statista. This expansion is largely driven by key markets like the United States, which is expected to generate $179.80 billion in medical device revenues in 2024 alone. In this expanding market, one company gaining attention is Therma Bright Inc. (OTCQB: TBRIF) (TSXV: THRM), a developer and partner in cutting-edge diagnostic and medical device technologies. Key Achievements and Market Positioning On July 3, 2024, Therma Bright provided a significant market update, underscoring major milestones achieved in Q2. A critical development was the successful securing of CAD $1,000,000 through a private placement, demonstrating strong investor confidence. These funds are allocated towards developing the Digital Cough Analyzer (DCA) and increasing the company’s stake in InStatin Inc., reflecting strategic moves across multiple high-growth markets. Therma Bright’s CEO, Rob Fia, highlighted that the proceeds would also support investor relations efforts and general working capital, emphasizing the company’s robust outlook. Venowave VW5: FDA Approval and Anticipated CPT/HCPCS Codes A major milestone for TBRIF in Q2 was the FDA’s approval of its 510K application for the Venowave VW5, a medical compression device designed to improve circulation in the lower extremities. This approval is pivotal as it meets the U.S. Centers for Medicare and Medicaid Services (CMS) requirement for issuing permanent CPT and HCPCS codes. The Venowave VW5 is a lightweight, discreet device that addresses circulatory issues such as deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS). The market for DVT treatments alone is estimated to reach USD $1.554 billion by 2032, making this approval a significant achievement for Therma Bright. “With the FDA 510K application approval and CMS code designation recommendations complete, we anticipate the Venowave’s permanent codes approval imminently,” said Fia. “Our distribution partners are ready to deploy the Venowave to Medicare and Medicaid medical practitioners, offering an effective solution for patients suffering from various circulatory issues.” Awaiting CMS Approval: A Key Growth Catalyst As of August 1, 2024, Therma Bright received positive notification from CMS regarding the pending permanent CPT and HCPCS codes for its Venowave VW5 device. These codes are expected to cover ten critical health-related indications, from DVT prevention to enhancing blood circulation. The confirmation of these codes, anticipated in the coming days, will enable Therma Bright to fully leverage insurance reimbursements, significantly expanding its market reach. “We’re patiently awaiting confirmation from CMS, which is expected in a matter of days,” said Fia. “The approval of these permanent codes will be a game-changer for our distribution strategy and market penetration.” The confirmation of these codes is a pivotal opportunity for TBRIF because it allows the Venowave VW5 to be covered by insurance, making it more accessible to patients and more attractive to healthcare providers. This expansion into the insured market can significantly boost sales, revenue, and market presence, positioning Therma Bright as a leader in the circulatory health market. Digital Cough Analyzer (DCA) Powered by AI4LYF Therma Bright’s advancements are not limited to circulatory health. The company is also progressing with its AI-powered Digital Cough Analyzer (DCA). Positioned as a remote therapeutic monitoring solution, the DCA is poised to tap into the growing global respiratory monitoring market, which is expected to nearly double, reaching USD $2.99 billion by 2032. Plans are in place to work closely with the FDA on regulatory requirements, positioning the DCA as a key player in respiratory health technology. Strategic Investments in InStatin and Inretio TBRIF continues to enhance its portfolio through strategic investments in companies developing cutting-edge solutions in chronic lung disease management and ischemic stroke treatment. The company’s significant stakes in InStatin Inc. and Inretio are particularly noteworthy. The global markets for asthma treatment and coronary stents are projected to reach USD $30.1 billion and USD $4.8 billion by 2030 and 2029, respectively, highlighting the potential impact of these investments. Fia expressed optimism about these ventures, noting that InStatin’s innovative solution for chronic lung conditions, including asthma and COPD, could deliver substantial returns for shareholders. Conclusion Therma Bright Inc. (OTCQB: TBRIF) (TSXV: THRM) stands at an important moment in the medical device industry, with its innovative approaches positioning it for potential growth. The company’s advancements, including the anticipated CMS code approvals for the Venowave VW5, underscore its ability to capitalize on opportunities. By securing key regulatory approvals and investing in cutting-edge technologies, Therma Bright is not only enhancing its market presence but also setting the stage for transformative success. As the company continues to lead with solutions in circulatory health and respiratory monitoring, it presents an interesting investment opportunity. Savvy investors may want to closely monitor Therma Bright’s progress as it navigates this dynamic sector and drives forward with its ambitious growth strategy. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and expects to be compensated by Therma Brite to assist in the production and distribution of content related to TBRIF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website https://razorpitch.com/

August 12, 2024 06:00 AM Eastern Daylight Time

All Industries

Goodway Cares Donates Over $27K to Local Washington D.C. Charities During Bi-Annual Off-Site

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder

Open Letter Demands ‘Newsroom Reset’, Pushes for Adoption of Pro-Democracy Election Coverage Guidelines

Benchmark International Unveils the 2024 Global Healthcare & Medical Industry Report

Elf Labs’ CEO Opening Live Q&A for Investors Amid Private Capital Raise

Revenue Management Solutions Named “Best Use of Research and Surveys” In PR Daily’s 2024 Social Media, Digital & Content Marketing Awards

Innovayte and Advyzon Partner to Create Single, State-of-the-Art Technology Solution

Black Unicorn Factory Achieves $500 Million Milestone in Alternative Funding, Signaling a New Era in Venture Capital

Therma Bright Inc. (OTCQB: TBRIF) (TSXV: THRM): Pioneering Growth in the Expanding Medical Devices Market